Document is current
Any future updates will be listed below
-
Authors
Daetwyler, Eveline https://orcid.org/0000-0001-5800-6446
Wallrabenstein, Till https://orcid.org/0000-0002-6672-3135
König, David https://orcid.org/0000-0003-3559-6855
Cappelli, Laura C
Naidoo, Jarushka
Zippelius, Alfred https://orcid.org/0000-0003-1933-8178
Läubli, Heinz https://orcid.org/0000-0002-8910-5620
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05414552 at ClinicalTrials.govnct04438382 at ClinicalTrials.govDocuments that mention this clinical trial
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
nct03619876 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
https://doi.org/10.1136/jitc-2021-002435
Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-001884
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
https://doi.org/10.1136/jitc-2020-001731
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
https://doi.org/10.1136/jitc-2022-004670
Documents that mention this clinical trial
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
- License Information
